CASP3 and pancreatic neoplasm: The H5 formulation was found to have a high stability in vitro, low drug release in plasma ex vivo and the highest cytotoxic activity for pancreatic cancer cell lines, as demonstrated by its ability to induce apoptosis by both ROS generation and activation of caspase 3/7 in the two PA cell lines tested.